Institutional Core Labs
- iLab
- Bioanalytics & Single-Cell
- Biospecimen and Translational Genomics
- Flow Cytometry
- Mass Spectometry
- Optical Imaging
- Structural Biology (NMR)
- Structural Biology (X-Ray Crystallography)
Find a Researcher
Research by School
VPR Applications Support & IT
Additional Resources
- Environmental Health & Safety
- Council of Principal Investigators
- National Academy of Inventors
- Office of Technology Commercialization
- Postdoc Positions
- Report A Discovery
- Research Directory
- Researcher Resources
- San Antonio Bioscience Research
- San Antonio Partnership for Precision Therapeutics
- Spotlight on Research Integrity
Oral Cancer
Oral cancers are common, with approximately 400,000 new cases and 200,000 deaths worldwide in 2013.
Approximately 42,000 new cases and almost 8,000 deaths from oral cancers were estimated to occur in the United States in 2012. More than 90 percent of these cases were oral squamous cell carcinomas (OSCC). The overall five-year survival rate of OSCC patients is approximately 57 percent. The prognosis of OSCC patients is adversely influenced by cancer recurrence, which happens in 5 to 50 percent of patients.
The Latest Facts & Findings
One person dies of oral cancer every hour of every day. Historically oral cancer has been associated with the chronic and excessive use of tobacco and alcohol. More recently it has been shown that Human Papilloma Virus (HPV) infection is also associated with oral cancer. Capsazepine is a synthetic pain receptor antagonist that was discovered to have significant anti-tumor effects in animal models of oral cancer.
Oral cancer is
a significant health problem in South Texas, as mortality in Hispanic South Texans is much higher than state and national averages.
In the last 40 years
patient prognosis has improved only slightly, yet the incidence of oral cancer continues to increase.
Dr. Cara Gonzales recently discovered that capsazepine, a synthetic pain receptor antagonist, not only blocks pain but also has significant anti-tumor effects in animal models of oral cancer.
Additional Highlights
-
Innovative Biopsy
We are developing a non-invasive brush biopsy test for oral cancer using Lab-on-a-Chip technology that can be performed in 15 to 30 minutes at a patient’s first appointment.
Nano-Bio-Chip Sensor Platform For Examination of Oral Exfolliative Cytology -
Prevention Studies
Studies evaluating the efficacy of supercritical CO2 neem extract taken from the neem tree (Azadiracta indica) for prevention of oral cancer are under way.
-
Therapeutic Studies
Studies evaluating novel therapies co-targeting epigenetically regulated signaling pathways in oral cancer are being conducted by Dr. Cara Gonzales with Dr. Tim Huang and Dr. Nameer Kirma from the Department of Molecular Medicine.
A recent study published in Carcinogenesis. -
Epidemiology Studies
The epidemiology of HPV associated oral cancer has been described in many U.S. regions, but not in South Texas. Dr. Spencer Redding and Stephanie Rowan lead studies to define the epidemiology here, particularly in the Hispanic population.
Prevalence of HPV Associated Oropharyngeal Cancer among South Texans